We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19. Each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19.
More than $221 million ARC Discovery Projects announced for 2023 Grant Announcement — $39 million awarded to build research infrastructure, equipment, and facilities The Australian Research Council (ARC) Chief Executive Officer, Ms Judi Zielke PSM, today announced more than $39 million in…
Học máy (tiếng Anh: machine learning) là một lĩnh vực của trí tuệ nhân tạo liên quan đến việc nghiên cứu và xây dựng các kĩ thuật cho phép các hệ thống "học" tự động từ dữ liệu để giải quyết những vấn đề cụ thể. Ví dụ như các máy có thể "học" cách phân loại thư điện tử xem có phải thư rác (spam ...
During May 30–November 20, 2021, incident cases were defined using a positive nucleic acid amplification test (NAAT) result from the California COVID-19 Reporting System (CCRS) or a positive NAAT or antigen test result from the New York Electronic Clinical Laboratory Reporting System. In California, person-level hospitalization data …
Dupilumab significantly improved atopic dermatitis signs and symptoms versus placebo in children younger than 6 years. Dupilumab was well tolerated and showed an acceptable safety profile, similar to results in older children and adults. ... Qualified researchers may request access to study documents (including the clinical study report, …
Oct'21 Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct'22 Table A. Percent changes in CPI for All Urban Consumers (CPI-U): U.S. city average 1 Not seasonally adjusted. - 3 - Food . The food index increased 0.6 percent in October following a 0.8-percent increase in September. The
Americans with disabilities less likely than those without to own some digital devices September 10, 2021. All reports and blog posts related to mobile technology. 1615 L St. NW, Suite 800 Washington, DC 20036 USA (+1) 202-419-4300 | Main (+1) 202-857-8562 | Fax (+1) 202-419-4372 | Media Inquiries.